An integrated system for diagnosing neoplasms with the help of artificial intelligence is undertaken by the consortium SYNERGY VALUE – WITSIDE – ISTOMEDICA
The project, called AI-PathoLab, is funded by the General Secretariat for Research and Innovation. It has a budget of € 441,030.00 and a total duration of 30 months.
The Project is expected to contribute substantially to:
Faster and safer evaluation of histological samples
immediate treatment with beneficial effects on patients life quality
Improving public health
More specifically, the AI-PathoLab platform utilizes the capabilities of Artificial Intelligence to:
Recognize neoplastic data on digital photographs from processed histological specimens.
Categorize and classify the findings, quantitatively and qualitatively.
Evaluate all the data, thus proceeding to the diagnosis and staging of the disease.
Focus on two types of cancer. Thyroid cancer and prostate cancer.
Mr. Christos Papadopoulos, CEO of WITSIDE and Scientific Officer of the Project, told us: “People are entitled to more accurate diagnoses and targeted treatments at low cost. In this project, we combine interdisciplinary knowledge and skills to improve the lives of patients and their families. “
Mr. Nikos Goutas, Doctor of Pathology, Associate Professor of NTUA and co-owner of Istomedica stated: “Through AI-PathoLab, we aim to provide young physicians with high-level know-how, as well as a powerful digital tool that will help in the valid and timely diagnosis of neoplasms.”
The Commercial Director of Synergy Value, Mr. Yannis Syrimpeis stated: “At Synergy Value our interest in innovative applications and cutting-edge technologies is intense. AI-PathoLab combines our passion for new solutions, our experience in healthcare applications and the hope of enhancing medical diagnostic tools.”
other top quality content posts on the blog.